Arbutus Biopharma

370 articles with Arbutus Biopharma

• Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

  1/4/2021

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 – 14, 2021. Arbutus Fireside Chat Pr

• Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects

  12/10/2020

  Arbutus Biopharma Corporation today announced additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

• Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects

  11/16/2020

  Results support advancement into Phase 2 combination clinical trialswith AB-729 dosing as infrequently as every 8 or 12 weeks

• Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting

  11/15/2020

  Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted

• Arbutus to Present at Jefferies Virtual London Healthcare Conference - Nov 10, 2020

  11/10/2020

  Arbutus Biopharma Corporation announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:35 pm EST.

• Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/5/2020

  Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference

• Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference

  9/28/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 1:00 pm ET. Arbutus Fireside Chat

• Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg

  9/15/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today reports continued positive data from an ongoing Phase 1a/1b clinical trial (AB-7

• Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

  8/27/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI-H0731 in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor

• Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/7/2020

  Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies by the end of 2020 Actively screening multiple new molecular entities in recently initiated COVID-19 research program Cash runway guidance extended into mid-2022 Conference Call and Webcast Scheduled Today at 8:45 AM ET

• Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

  8/5/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 3:30 PM E

• Arbutus to Report Second Quarter 2020 Financial Results

  7/29/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020.  The schedule for the press release and conference call/webcas

• Arbutus to Present at Jefferies Virtual Healthcare Conference

  5/27/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 PM ET. A live webcast of the presentation can be accessed through the Investors section

• Arbutus to Present at UBS Virtual Global Healthcare Conference

  5/12/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 11:40 AM ET. A live webcast of the presentation can be accessed through the Investors section

• Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections

  5/11/2020

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus infection, reports its first quarter 2020 financial results, provides a pipeline update and announces the establishment of a new research initiative focused on the identification of novel therapies to combat COVID-19.

• Arbutus to Report First Quarter 2020 Financial Results

  5/4/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 11, 2020. The schedule for the press release and conference call/webcast are as follows: • Q1 2020 Press Release: May 11, 2020 at 6:00 a.m. ET • Q1 2020 Conference Call/Webcast: May 11, 2020 at 8:00 a.m. ET • Do

• Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results

  2/27/2020

  Arbutus Biopharma Corporation, a Hepatitis B Virus therapeutic solutions company, announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for Thursday, March 5, 2020.

• Arbutus to Report Third Quarter 2019 Financial Results

  10/30/2019

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November 6, 2019.

• Arbutus to Present at Chardan’s Genetic Medicines Conference

  10/2/2018

  Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 2:45 pm – 3:10 pm ET in New York.

• Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis

  8/13/2018

  ONPATTRO Approval Triggers Royalty to Arbutus